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At birth testicular androgens irreversibly program brain centers involved in hypothalamo-
pituitary control of hepatic sex-dependent steroid and drug metabolism. This imprinting
process results in activation of a hypothalamic "feminostatin"-a secreting center that is
turned onjust before puberty. Feminostatin inhibits pituitary secretion of "feminizing factor,"
a pituitary hormone that feminizes the basal type of metabolism characterizing the liver of
hypophysectomized and gonadectomized rats. Consequently, female rats that are devoid of
feminostatin will secrete feminizing factor from the pituitary, leading to a feminine type of
hepatic metabolism. Male rats have an active feminostatin-secreting center, and inhibition of
pituitary feminizing factor release results in an autonomous type of liver metabolism. Female
rats show a relative androgen unresponsiveness and seem incapable of releasing feminostatin
after treatment with natural androgens, possibly because of more efficient metabolism
(breakdown) of androgen in the female than in the male rat brain.
Frontal deafferentation at the retrochiasmatic and suprachiasmatic level resulted in a
complete "feminization" of hepatic steroid metabolism in male rats. Such an effect was also
seen when lesions involving mainly the anterior periventricular hypothalamic area and the
suprachiasmatic nucleus were performed in male rats. No effects were seen in analogous
lesions in female rats in any ofthe cases studied. These findings suggest that a region including
the anterior hypothalamic periventricular area, the suprachiasmatic nucleus and adjacent
areas is involved in the control ofhepatic steroid metabolism. It is postulated that the neuronal
cell bodies that produce feminostatin have their origins in this area ofthe hypothalamus or may
send axons through this area to the basal hypothalamus and thus directly or indirectly
influence the anterior pituitary gland.
Regulation by the central nervous system of a "lactogenic" (prolactin, Prl) receptor, present
in the female rat liver, was also studied. This receptor is present in very low concentration or
absent in the male rat. Anterior hypothalamic deafferentation at the retrochiasmatic level in
male rats increased the hepatic Prl receptor concentration to the female level 3-4 days following
the operation. A transection rostral to the suprachiasmatic nucleus had no effect on the
concentration ofPrl receptors in male animals. Our results demonstrate that the number ofPrl
receptors is regulated by the hypothalamo-pituitary system. The receptor-inducing pituitary
factor might be related to the feminizing factor. Experiments were carried out to elucidate the
nature of the Prl receptor-inducing pituitary factor.
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April 1981 129Human growth hormone (hGH) continuously administered was shown to induce Prl
receptors in livers from male and female hypophysectomized-gonadectomized rats. The
prolactin receptors were increased to a level found in control female rat livers. This inductive
effect of hGH was also seen in adrenalectomized and thyroidectomized male rats. The induced
Prl receptors in male rats had similar characteristics as hepatic Prl receptors in female rats.
Also the endogenous rat hormones, rPrl and rGH, were administered in minipumps. In the
concentration used (10 .g/4l), rPrl had no effect whereas rGH increased Prl receptor levels to
approximately 37% of the female control level. These results indicate that GH or a peptide
related to GH may be involved in the regulation of hepatic Prl receptors.
The hypothalamo-pituitary-liver axis represents a new concept in endocrine regulation of
drug toxicity. The male rat liver has been shown to be more susceptible than the female rat liver
to the hepatocarcinogenic action of certain drugs, and it is conceivable that sex differences in
the metabolic activation of the drugs in the liver may explain the greater sensitivity of male
rats to chemically induced hepatocellular carcinoma. Similar sex differences in liver cancer
incidence have been reported in the human.
Introduction
Primary liver cancer has been reported to be
more frequent in men than in women (1-4) and a
greater male susceptibility to the induction ofliver
cancerbycarcinogens such asN-2-fluorenylacetamide
has also been found in several rat strains (5-7).
Removal of the testes decreased the tumor inci-
dence in the experimental animals (8, 9) and substi-
tution with androgen restored the responsiveness
(8). Long-term treatment with androgenic steroids
has also been claimed to increase the risk for
development ofhepatocellular carcinomain humans
(10). In rats, testosterone was reported to act
indirectly via endocrine tissue(s) to increase chemi-
cal hepatocarcinogenesis (11). Recently, Toh found
that bilateral electrolytic lesions placed in the
median eminence area ofthe hypothalamus in adult
male rats had an inhibitory effect on liver tumor
induction by N-2-fluorenylacetamide (12). This ex-
periment indicated a role of the hypothalamus in
determining the susceptibility of the liver to toxic
agents.
Since several years we have been involved in
studies on mechanisms involved inregulation of sex
differences in hepatic metabolism of steroids and
drugs(13). Based on ourfindings, wehavesuggested
the existence of a novel endocrine control system,
the hypothalamo-pituitary-liver axis, of major im-
portance in regulation of hepatic metabolism. It is
apparent to us that the results on liver toxicity
described above may well be understood in view of
this new concept of control of liver function and
therefore the present paper will review some
aspects of hypothalamo-pituitary regulation of he-
patic metabolism.
Central Control of Hepatic Steroid
and Drug Metabolism
In the early 1950's, Hubener and Amelung (14)
showed a sex-related difference ofhepatic cortico-
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steroid metabolism in the rat. This finding was
substantially confirmed bysubsequentreportsusing
corticosteroids (15-17), androgens (16-18), and es-
trogens (18) as substrates. Male animals show a
higherhydroxylating activity than females (17, 18),
whereas females exhibit a higher 5oa-reductase
activity (16). Somewhat later, Yates et al. (16)
published the first study indicating that androgens
were involved in the control of steroid metabolism
in rat liver. It was found that castration increased
and testosterone treatment decreased the 5a-
reductase activity. This finding was confirmed and
extended by Gustafsson and Stenberg (19-22), who
showed the dependence ofthe adult male pattern of
metabolism on the presence of neonatal androgen
(imprinting). Although dependent on neonatal an-
drogen exposure, no sex-related differences in
steroid metabolism were observed until 30 days of
age (23-27). Sex-related differences in metabolism
and the androgen-dependence of these differences
have also been observed for the metabolism of
variousdrugsandxenobioticsincludingethylmorphine
(28), aniline (29), p-nitroanisole (30), and hexo-
barbitone (31). The absence of any sex-specific
androgen receptor in the liver (32) coupled to the
fact that male animals are more sensitive to andro-
gen action as regards hepatic steroid metabolism in
the adult period (22, 33) seems to indicate an
indirect action of androgen on hepatic steroid
metabolism.
A possible explanation of the indirect action of
androgens on hepatic steroid metabolism was put
forward in 1974, when Denef (34) and Gustafsson
and Stenberg (35) published the effects of hypo-
physectomy on hepatic steroid metabolism. Both
groups showed that hypophysectomy of female
animals resulted in a male pattern of metabolism,
indicating that the female pattern ofmetabolism is
dependent on the presence ofan intact pituitary. It
is well known that the hypothalamus in the rat is
sex-differentiated with regard to control of pitu-
itary secretion (36) and thus it is likely that the
Environmental Health Perspectivessex-related difference in hepatic steroid metabo-
lism observed is secondary to the sexual differenti-
ation ofthe brain at birth and that androgens have
their action via the hypothalamo-pituitary axis
rather than directly on the liver. The pituitary
dependence ofhepaticmetabolism is not confined to
steroid metabolism although both androgen (34, 35)
and corticosteroid (37) metabolism are involved.
Kim et al. (38) have shownthat protein demethylase
II activity in the rat liver is pituitary-dependent
and there is evidence to support the pituitary
dependence of drug and xenobiotic metabolism,
including that ofethylmorphine (39, 40). The basal
hepatic lipolysis (41) and synthesis of plasma pro-
teins (42) have also been shown to be controlled, at
leastpartially, bythe pituitarygland. Krameretal.
(39) have shown that the effect of testosterone on
ethylmorphine metabolism is not manifested in the
absence of the pituitary gland. A similar observa-
tion was seen in the study of Gustafsson and
Stenberg (35) where neither testosterone nor 1713-
estradiol had any major effects on hepatic steroid
metabolism in hypophysectomized rats. It thus
seems likely that the effects ofthe sex steroids on
hepatic metabolism are indirect and are effectuated
via the hypothalamo-pituitary axis.
Implantation of a pituitary gland under the
kidney capsule of a hypophysectomized male or
female rat resulted in feminization of the host's
hepatic steroid metabolism (34, 43). We also showed
that different time periods were required for the
changes in different enzyme activities (44), empha-
sizing the importance of the sensitivity of the
respective enzyme system to the controlling fac-
tor(s). This would seem to indicate that the ectopic
pituitary gland secretes a factor into the general
circulation that is normally only secreted by the
female pituitary gland insitu. The ectopicpituitary
tissue is known to secrete prolactin and growth
hormone and small amounts of the other anterior
pituitary hormones (45-48). In our experiments
only prolactin and growth hormone could be mea-
sured in the serum of implanted animals (44). The
hypophyseal factorresponsible forthe maintenance
ofthe female-type ofhepatic metabolism is, as yet,
an open question.
A number of reports have been published show-
ingeffects ofvarious purified pituitary hormones or
combinations of hormones on drug and steroid
metabolism in the rat. Gustafsson and Stenberg
(49, 50) have shown an effect of FSH but no effect
of LH or prolactin on hepatic steroid metabolism
when 4-androstene-3,17-dione is used as substrate.
These results are in agreement with those ofColby
et al. (37), where corticosterone was used as
substrate, and gain further confirmation from the
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study of Lax et al. (45), where the effect of
prolactin on reductive metabolism was examined.
In the report of Colby et al. (37), a combination of
GH and ACTH decreased reductive metabolism (an
effect similar to hypophysectomy), while Lax et al.
(51) found that prolactin had this effect. A later
report by Kramer and Colby (52) indicated that GH
alone increased reductive metabolism of steroids
(an effect dramatically opposite to that of GH
combined with ACTH). In the field ofdrugmetabo-
lism, ACTH and GH seem to be the most active.
GH alone was thought to reduce the hepatic metab-
olism of ethylmorphine (52, 53) and aminopyrine
(53), whereas combinations ofACTH and GH have
been shown to increase the carcinogenicity of
N-hydroxy-N-2-fluorenylacetamide (54, 55) (there-
by indicating a decrease in dehydroxylation and
deacetylationofthecarcinogenbytheliver). Kramer
et al. (56) have reported that both LH and FSH,
when given to castrated male and female rats,
increased ethylmorphine demethylase activity in
the liver.
None ofthe above mentioned effects are, howev-
er, as marked as that seen after implantation of a
pituitary gland under the kidney capsule. These
data would indicate that the control of hepatic
steroid and xenobiotic metabolism is mediated via
an, as yet, unidentified pituitary factor (or possibly
an unidentified combination of factors)-we have
labelled this factor "feminizing factor" or "femin-
otropin." The purification ofthis factoris underway
in our laboratory.
Studies by our group (57, 58) on the ontogenesis
of the pituitary control of hepatic steroid metabo-
lism have indicated that the liver and pituitary are
not per se sex differentiated with regard to their
response to and production of "feminizing factor,"
respectively. Thus, the masculinized ("imprinted")
control center must lie elsewhere.
The possibility that hepatic steroid metabolism is
under indirect hypothalamic control was first indi-
cated by our above-mentioned finding (59) that
complete electrothermal destruction of the hypo-
thalamus in male rats resulted in "feminization" of
the steroid metabolism in the liver ofthe operated
animals. This indicated forthe firsttimethat, inthe
male rat, release of the factor(s) maintaining a
female-type steroid metabolism in female animals
was inhibited by the hypothalamus. This inhibitory
control is similar to that ofprolactin, the release of
which is inhibited by prolactin release inhibiting
factor (PIF) (60).
The site of the sexual differentiation in the
hypothalamus appears to lie predominantly in the
preoptic area where, in fact, anatomical differences
in nerve structure can be found. Greenough et al.
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FIGURE 1. Diagrammatic representation of the level of
deafferentation used. Deafferentation at the retrochiasmatic
level caused complete "feminization" of hepatic steroid me-
tabolism: (CO) optic chiasma, (HA) anterior hypothalamic
nucleus, (S) suprachiasmatic nucleus, (HVM) ventromedial
nucleus, (AR) arcuate nucleus, (M) mamillary body.
(61), on studying the hamster preoptic area, found
different patterns ofdendrite density corresponding
to different afferent inputs to the dorsomedial
preoptic area. In addition, many reports have been
published on the sex differences in hypothalamic
structure and their relation to neonatal androgen
exposure (62-65).
In order to ascertain more exactly the area ofthe
hypothalamus that controls the secretion offeminiz-
ing factor, a series of experiments was performed
by our group (66) whereby the effects of various
brain lesions on hepatic steroid metabolism were
investigated. Two distinct types of lesions were
perforned: one, anteriorhypothalimicdeafferentation
and two, discrete lesions in the rostral parts ofthe
hypothalamus. One week after the lesioning, the
animals were killed and their hepatic steroid me-
tabolism investigated. The effects ofthe lesions on
steroid metabolism were correlated to the changes
in secretion of pituitary hormones.
Hypothalamic deafferentation about the level of
A5660,u [according to the atlas of Jacobovitz and
Palkovits (94)] (posterior to the preoptic area and
thus separating the rostral parts ofthe hypothala-
mus from the medial basal hypothalamus including
the median eminence) (Fig. 1) caused complete
"feminization" ofhepatic steroid metabolism in the
operated male animals while having little effect on
the female animals (66). These results indicate that
the center of control lies anterior to the level of
A5660,u, possibly in the suprachiasmatic nucleus or
inthe surroundingperiventricular area. This finding
is in contrast to the proposed regulatory site for
prolactin secretion which lies within the boundaries
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of the deafferentation. In order to further investi-
gate the possible involvement of the hypothalamic
areas, a number of discrete lesions were placed in
various positions in this area and their effects on
hepatic steroid metabolism studied. Acomparative-
ly large midline lesion placed in the periventricular
region and stretching between levels A719O0, and
A566O1j. (i.e., roughly located anterior to the level
of the deafferentation) caused complete feminiza-
tion ofsteroid metabolism in the livers ofoperated
male animals while having only small effects on
female animals. However, lesions inthe midline but
occupying only the more rostral aspects of the
lesion mentioned above (stretching from levels
A789O0, to A6670,u) were without effect indicating
that the essential areas involved in the control of
the secretion offeminizing factor lie caudally to the
level A667O0,; i.e., approximately extending from
the beginning of the suprachiasmatic nucleus in a
caudal direction.
Bilateral lesions essentially involving the nuclei
interstitialis striae terminalis but also extending
medially including the anterior commissure caused
a moderate degree of feminization indicating that
higher centers may be involved in the regulation of
the secretion of feminizing factor. Small bilateral
lesions in the lateral preoptic area were without
effect on steroid metabolism in the livers of the
lesioned rats.
The question may now be asked whether the
effects ofandrogens and estrogens on the livermay
be mediated via the hypothalamus. Much work has
been done on the presence of receptors for sex
steroids in the brain particular as regards the
hypothalamus. We have shown the existence of
specific androgen receptors in several brain regions
including the hypothalamus, cortex and pituitary
gland (67). In the same study we found that there
appears to be a sexual dimorphism of androgen
metabolism in rat brain (67). Testosterone was
metabolized predominantly to androstenedione in
the male but to 5a-androstane-3a(or 3,B), 17p-diol,
epitestosterone and dihydroepitestosterone in the
female. The metabolism of testosterone was also
much faster in female than male brains. This could
explain the relative androgen unresponsiveness in
the female.
With regard to the actions ofestrogens, it is well
accepted that specific estrogen receptors exist in
the hypothalamus and that binding of estrogen to
these receptors can cause biochemical and physio-
logical changes in the receptor-containing brain
areas. We have recently developed a highly sensi-
tive and specific method for estradiol receptor
quantitation, based on isoelectric focusing in
polyacrylamide gel, and we have used this method
Environmental Health Perspectivesto study sexual differences in distribution of estra-
diolreceptors in the brain (68). The highest concen-
trationsofestradiolreceptorwerefoundinamygdala
and anterior and posterior hypothalamus.
All ofthese data would seem to indicate that the
hypothalamus (and pituitary gland) is capable of
reacting to estrogens (in both sexes) and androgen
(only in the male). It is thus likely that most, ifnot
all, effects ofsex steroids on hepatic steroid metab-
olism are indirect and mediated via the hypo-
thalamo-pituitary system. Furthermore, it is the
hypothalamus that is imprinted at birth by andro-
gens exactly as has been demonstrated forthe adult
patterns of sexual behavior and release of gonado-
tropins.
Ourproposed theory forthe imprintingofhepatic
steroid metabolism in the rat is shown in Figure 2.
Imprinting occurs entirely in the hypothalamus
where androgen in the neonatal period alters the
anatomical, physiological and biochemical workings.
This area, which we have labeled the "feminostatin"
center, since we think it produces the feminizing
factor release-inhibiting factor, is only active in the
male. Androgen in the neonatal period is essential
for activation of the center. In the normal adult
male, the activated feminostatin center produces
and releases feminostatin which, in turn, inhibits
the release of feminizing factor from the pituitary
gland. This leads to a masculine pattern ofhepatic
metabolism. In the female, the feminostatin center
is inactive, and thus feminizing factor is released
from the pituitary gland giving a feminine pattern
ofhepatic metabolism. Androgens are active in the
male in the adult period by interaction with the
androgenreceptors in the brain while estrogens are
active in both sexes via the estrogen receptors in
the hypothalamus and pituitary gland. It is proba-
ble that the effects ofthe sex steroids are mediated
via the feminostatin center, but a direct effect on
the pituitary gland cannot be ruled out.
Central Control of Prolactin (PrI)
Receptors in the Liver
During recent years, we have studied another
sex-differentiated liver function quite extensively,
namely the concentration ofprolactin receptors. It
has become more and more evident that also this
system is controlled by the hypothalamo-pituitary
axis and that, indeed, the feminizing factor or a
similar factor may be responsible for the mainte-
nance ofprolactin receptors in the female rat liver.
Some ofour recent findings on regulation ofhepatic
prolactin receptors will be presented below.
In 1974, Friesen's group showed the existence of
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FIGURE 2. Proposed model for the control and imprinting of
hepatic steroid metabolism in the rat. T denotes testoster-
one.
a receptor in rat liver that bound both ovine
prolactin and human growth hormone (69, 70). It
was found that this receptor was present in much
higher concentrations in female than male rats.
These findings have been confirmed by other groups
including our own (71-74).
The development of these receptors has been
shown to follow that of the steroid-metabolizing
enzymes rather closely. No sex differences were
found in lactogenic receptor concentration in
prepubertalrats, but between20 and 40 days ofage
a marked increase in the receptor level in female
rats occurred (there was no concomitant change in
the male) (70). This should be compared to the
development of, for example, the 5a-reductase
(active on 4-androstene-3,17-dione) (27); this en-
zyme wasfoundinlowconcentrationsinprepubertal
rats but developed rapidly in females around 30
days ofage leading to the marked sex differences in
activity noted in the adult period.
The level of "lactogenic" receptors in rat liver
seemed to depend upon the level of androgen and
estrogen. Ovariectomy reduced and castration in-
creased the number of "lactogen" binding sites
whereas replacement therapy with the appropriate
steroid reversed the effect ofthe glandular ablation
(72, 75, 76). Male animals injected with estrogens
showed a marked increase in "lactogenic" binding
while females treated with testosterone displayed
lower binding than controls. This again is a very
similar situation to that found for the enzymes
133responsible for the metabolism of steroids and
drugs in the rat liver, as discussed above.
Further work by Friesen et al. (75) and others
(71) has shown that, even in this system, the
pituitary gland has some role to play. Removal of
the pituitary gland of female animals led to a
reduction in the concentration of receptors to a
male level whereas similar treatment of male ani-
mals was essentially without effect. Treatment of
hypophysectomized males with estrogen was also
without effect, indicating that the estrogen may be
acting in an indirect fashion via the hypothalamo-
pituitary axis or that both estrogen and a pituitary
factor are necessary for the effect on the liver. It
would thus seem from the above data that the
effects of the sex steroids on hepatic "lactogenic"
receptors are indirect and are mediated via the
hypothalamo-pituitary axis.
What is the pituitary factor that maintains the
high level of"lactogenic" binding sites in the female
rat liver? Posner et al. (76, 77) have shown that
implantation of a pituitary gland under the kidney
capsule of a hypophysectomized female rat could
restore the original level of receptors, indicating
that, in a similar manner to hepatic xenobiotic
metabolism, the ectopic pituitary can secrete a
factor that maintains the female-type liver. The
time course of the effect of implantation of a
pituitary gland on lactogenic receptor level follows
very closely that of development of female steroid-
metabolizing characteristics following pituitary im-
plantation (78) but shows a marked lagperiod when
compared to the outflow of prolactin from the
transplant. It was suggested by Friesen that pro-
lactin itselfmay be the induceroflactogenic binding
in rat liver. This assumption was based on experi-
ments (71, 76, 78, 79) whereby the effects of
treatment with ovine prolactin, human growth
hormone and ACTH on lactogenic receptor level
were tested in hypophysectomized animals. Costlow
et al. (71) found a restoration of lactogenic recep-
tors in hypophysectomized female rats but only to
15% of the level found in control females, whereas
Friesen et al. (78) showed an almost complete
restoration of lactogenic binding in hypophysect-
omized female animals, by treating with a mixture
of ovine prolactin and human growth hormone or
ACTH and human growth hormone (human growth
hormone itselfwas, however, a bad inducer, as was
ACTH). In male animals (79), a mixture of human
growth hormone and ACTH was the most effective
in inducing lactogenic receptors. A growth hor-
mone-producing tumor(GH12C,) was also shown to
induce lactogenic binding in male rats, indicating an
apparent role ofgrowth hormone in the regulation
of these receptors. Other pituitary tumors have
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been shown toinducelactogenic receptorsincluding
theprolactin-producingMtT/F4andMtT/W5tumors
(76). It is interesting to note that both of these
tumors have also been shown to feminize the rat
liver with regard to steroid metabolism (80).
The hypothesis put forward that prolactin regu-
lates the lactogenic receptors in rat liver no longer
seems to hold true following the work of Posner
(76), who showed that replacement therapy with
pure ovine prolactin was without effect in hypo-
physectomized animals. Recently, treatment of
hypophysectomized females bearing a pituitary
graft with the dopaminergic agonist, CB-154
(discussed above), has been shown to be ineffective
in eliminating the lactogenic receptor-inducing
capacity of the implant although serum prolactin
levels drop below the detectable limit (75).
In our own work (74-81), the prolactin-induced
lactogenic receptor concept has been consistently
challenged. We have also found no effect ofCB-154
on hepatic receptor level either in normal or
pituitary-transplanted animals. In addition, exten-
sive work involving hypothalamic deafferentation
has indicated no correlation between effect on
serum prolactin level and "lactogenic" receptor
level (see below).
Even the physiological ligand forthe "lactogenic"
receptor in rat liver is still in question. Friesen and
his group have assumed that binding of ovine
prolactin to rat liver is a measure ofthe binding of
rat prolactin to the same receptor. This does not
necessarily have to be the case, however, as
indicated by the work of Posner (76) where both
ovine prolactin and human growth hormone were
shown to be about five times as effective as rat
prolactin in displacing bound labelled ovine prolac-
tin. Rat growth hormone did not displace ovine
prolactin at all from the lactogenic receptor.
Ranke et al. (82, 83), working with isolated
hepatocytes, have shown that in this system rat
prolactin was also 10 times less effective than ovine
prolactin as a displacer and that rat growth hor-
mone was also ineffective as a displacing agent.
Other groups working with isolated cell systems
have shown binding of ovine prolactin and human
growth hormone (84, 85) but no regulatory studies
have yet been performed in this type of system.
To measure "lactogenic" receptor sites, we have
used 125I-labeled human Prl (Biodata, Coissons,
Switzerland), iodinated by the chloramine-T meth-
od (86) to a specific radioactivity of approximately
100 Ci/mg, as atracer. Incubations were carried out
within 3 weeks ofthe iodination date. Some decline
in apparent hormone binding, due to storage inacti-
vation of the ligand, was observed during this
period. Since no repurification of the iodinated
Environmental Health Perspectivesligand was performed, pooled microsomal mem-
brane fractions from female animals were included
in the experiments as a control. Each incubation
was carried out in 1.5 ml Eppendorf tubes
(Eppendorf, West Germany) containing 0.5 ml of
microsomal membrane suspension with 0.3-0.4 mg
ofprotein as determined bythe method ofLowry et
al. (87). The tracer (approximately 30,000 cpm) was
added in 0.1 ml of Tris buffer. Displacing agents
were added in 0.1 ml of Tris buffer. Samples were
slowly rotated for 22-24 hr at 4°C, after which the
incubation was terminated by centrifugation for 5
min in a microfuge B centrifuge at 10,000g. The tip
of the plastic Microfuge tube containing the pellet
was removed and counted in a gamma scintillation
counter. Routinely, each individual livermembrane
fraction from a group of animals was assayed by a
single point assay. For one animal in each group a
Scatchard plot was constructed (88) after correcting
for the protein concentration. As displacing agent,
ovinePrl(NIH-P-S-12)wasused, andwhenScatchard
analysis was performed, the displacing agent was
used in a range of 0.001-1 ,ug per incubation.
Nonspecific bindingwas defined asthe radioactivity
bound in the presence of1 ,ug oPrl. Specific binding
was calculated by subtracting nonspecific binding
from total binding. All incubations were performed
in triplicate or quadruplicate. Means and standard
deviations were calculated for the various experi-
mental groups and the degree ofsignificance calcu-
lated using Student's t-test. The level ofsignificance
was set at p < 0.05.
Hypophysectomy caused a marked reduction in
the number of hepatic hPrl receptors in female
animals. The receptors could partially be restored
by a pituitary implant under the kidney capsule.
The low binding in hypophysectomized female ani-
malsresembled thebindingfoundinmales. Scatchard
plots showed that hPrl receptor levels in the
experimental group with pituitary implants were
not completely restored to the control female level
(binding capacity 76 as compared to 165 fmole of
binding sites/mg protein) but that the KD was in
the same range (0.9 and 1.0 x 109M, respectively).
Experiments were also performed to study the
effect of hypothalamic lesions on hepatic hPrl
receptors. The effect of anterior hypothalamic
deafferentation on hPrl receptors in liver was
studied as a function of the length of the interval
between operation and decapitation (Fig. 3). Male
animals were deafferentated at the retrochiasmatic
level at different times so that all animals in the
experiment were killed at the same time. A group
of sham-operated animals was included. It was
found that suprachiasmatic deafferentation ofmale
rats led to an increase ofhepatic hPrl receptors to
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FIGURE 3. Time studies of (a) the effect of anterior hypotha-
lamic deafferentation on hepatic hPrl receptors in male rates
(specific binding in per cent ofthe total radioactivity vs. the
number of days after deafferentation) and (b) serum Prl in
animals following deafferentation (Prl concentration is given
in ng NIAMDD-RP-1/ml). Control groups of intact males
were included at 8 days. The numbers within brackets
indicate the number ofanimals assayed. The double asterisk
(**) indicates p* < 0.01; the triple asterisk (***) indicates p*
< 0.001 compared to control males.
the female level. The induction of hPrl receptors
was evident 3 days following the operation with a
maximum after 4 days (Fig. 3). The rise in the
concentration ofhPrl receptors in the liver was not
accompanied by an increase in serum Prl (Fig. 3).
Scatchard analysis showed that the induced recep-
tors in the lesioned male rats had similar ligand
affinity as the receptors in control female rats (KD
values 0.6 and 0.5 x 10-9M, respectively). Similar
binding capacities were also seen in lesioned males
and control females (81 and 102 fmole/mg, respec-
tively).
Inordertofurtherlocalizethe"receptor-regulating"
center(s) in the brain, transections were performed
at a more anterior level. The induction of hepatic
hPrlreceptorsfollowingalesionattheretrochiasmatic
level was not seen in animals with the more
anterior transection.
The results presented indicate that hypothalamic
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FIGURE 4. Effect on hepatic Prl receptors in hypophysectomized-gonadectomized rats of hGH administered in minipumps at a
concentration of5 p/,uil: (a) male hypophysectomized and castrated (Cx) rats; (b) female hypophysectomized and ovariectomized
(Uvx) rats. Male and female rats were hypophysectomized (Hx); one week later the rats were gonadectomized and, in the cases
indicated, given osmotic minipumps with hGH. After one week, the liver Prl receptors were measured. Included is also a control
group ofintact female rats. On the ordinate is the specific '25I-hPrl binding expressed in per cent oftotally added radioactivity.
Numbers within brackets indicate number of animals in each group.
deafferentation at the retrochiasmatic level severs
the connection between an inhibitory center in the
brain which under normal conditions depresses
pituitary secretion of a receptor-inducing factor in
the male. The exact localization ofthis brain center
remains to be determined. However, since no effect
was seen when transections were placed rostral to
the suprachiasmatic nucleus, this suggests that the
suprachiasmatic and preoptic area may be essential
for the control of induction of hPrl receptors. It
remains to be elucidated whether a "center" is
located in the area between the two levels of
transections or whether this area is traversed by
passing fiber systems coming in from the lateral
aspects to turn caudally towards the basal hypo-
thalamus.
The nature ofthe hypophyseal receptor-inducing
factor is uncertain. Retrochiasmatic deafferentation
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is likely to interfere with the LH-RH system;
destruction ofthe suprachiasmatic nucleushasbeen
reported to inhibit the phasic component ofthe LH
release (89). In view of the finding that castration
increases the Prl receptors (90), part ofthe hepatic
hPrl receptor induction following deafferentation
could possibly be a castration-like effect. However,
it is not likely that the large increase of hPrl
receptors after deafferentation could solely be a
castration-like effect, since castration alone does
notincrease the Prl receptors to afemale level (91).
The finding that high liver hPrl receptor levels
were not accompanied by high serum Prl levels
(Fig. 3), does not agree with earlier suggestions
that Prl could be the inducing agent of its own
receptor.
Using Alzet osmotic minipumps (Alza corpora-
tion, Palo Alto, Cal) (92) in the study ofhepatic Prl
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FIGURE 5. Effect of hGH on hepatic Prl receptors in
adrenalectomized and thyroidectomized rats. Male rats were
thyroidectomized (Tx) and adrenalectomized (Ax); the same
day some rats received minipumps containing 5 ,g hGH/,ul.
After one week, liver Prl receptors were measured and
serum collected forTSH analysis. Specific lmI-hPrl bindingis
shown on the ordinate. Numbers within brackets denote
number of animals in each group. Serum Tsh was: in d
Tx-Ax 1848 + 654 Fxg/ml, in d Tx-Ax-hGH 1968 349 ,g/ml,
in control Y 438 ± 99 ,ug/ml, in control d 606 317 ,ug/ml.
receptor regulation we have investigated the ef-
fects ofhGH, rGH, and rPrl under various experi-
mental conditions. These osmotic minipumps may
be placed subcutaneously in the dorsal neck region
ofthe animal and allow a continuous and long-term
(7 days) administration of hormone. The pumps
have a filling volume of 225 ,ul and a pumping rate
estimated to be 1 ,u/hr.
The effect of hGH placed in osmotic minipumps
on hepatic Prl receptor levels was tested in
hypophysectomized-gonadectomized male and fe-
male rats which are known to have low concentra-
tion ofPrl receptors in the liver (75, 90). A group of
untreated female rats was included in all of the
following experiments. As shown in Figure 4, hGH
induced a "feminine" Prl receptor level in livers of
hypophysectomized and castrated animals of both
sexes.
To ascertain that the effect of hGH was not
mediated via the adrenals orthyroids, these organs
were removed in male rats. The capacity ofhGH to
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FIGURE 6. Effect ofhGH onhepatic Prlreceptors as afunction
oftime inmale rats. Male animals carried osmotic minipumps
containing 5 ,i.g hGH/,ul during the time interval indicated.
Included is a group of female rats, the Prl receptor level of
which is indicated with a dotted line. Numbers within
brackets indicate number ofanimals. Specific '25I-hPrl bind-
ing is shown on the ordinate.
induce a "feminine" hepatic Prl receptor level was
unchanged in thyroidectomized-adrenalectomized
rats (Fig. 5) when compared to hypophysectomized-
gonadectomized animals.
The Prl-receptor-inducing effect of hGH, which
apparently did not require the presence of pitu-
itary, thyroid, adrenals or gonads, was then inves-
tigated in intact male rats with regard to its time
course (Fig. 6). An increase ofthe receptor concen-
tration to a female level was observed after 4-7
days of hGH administration.
The induced Prl receptors had similar character-
istics as the receptors present in control females
whencalculatingdataaccordingto Scatchard [Kd =
0.13 x l0e vs. 0.15 x 109M; number of binding
sites 88 vs. 57 fmole/mg protein (not shown)].
Figure 7 shows the effect of varying concentra-
tions of hGH in minipumps on receptor levels in
male rats. Induction to female Prl receptor levels
was seenwith2.5 pug/pi and 5 ,ug/,l (or5mU/,uland
10 mU/,ul, respectively).
The effects of rat hornone preparations were
then investigated. Rat GH and rat Prl were
administered to hypophysectomized male rats in
osmotic minipumps (10 ,ug/,l). A biological effect of
this concentration ofrGH was indicated by the fact
that the animals given rGH increased in weight
during 6 days to 114 + 4% of their initial weight.
This may be compared to the weight gain observed
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FIGURE 7. Effect ofvarying concentrations ofhGH on hepatic
Prl receptors in male rats. hGH, in concentrations indicated
on the abscissa, was placed in minipumps which were given
to male rats. One week later, Prl receptors were measured.
The ordinate shows the specific '2I-Prl binding. Numbers
within brackets indicate number of animals in each group.
The dotted line shows Prl receptor level in female control
group.
in hypophysectomized-gonadectomized rats given
hGH: 111 4% (from experiment shown in Fig.
4a). Hypophysectomized control rats or animals
given rPrl showed no weight increase. Administra-
tion of rGH to hypophysectomized rats increased
serum levels of GH from 22 ± 5 ng/ml to 64 ± 22
ng/ml. Administration ofrPrl resulted in serum Prl
levels of28 ± 17 ng/ml as compared to the levels in
hypophysectomized controls which were less than
2.5 ng/ml.
Administration of rPrl did not affect hepatic Prl
receptor levels in hypophysectomized male rats
(Fig. 8). However, some induction of Prl receptors
was observed following administration of rGH.
Scatchard analysis revealed a specific Prl binding
capacity of33fmole/mgprotein in rats givenrGH as
compared to 90 fmol/mg in control females; the Kd
values were 0.18 x 109M vs. 0.15 x 109M,
respectively. Thus, rGH could not induce Prl recep-
tor levels in hypophysectomized rats to the maxi-
mal, "feminine" level.
The results presented above indicate that an
induction of hepatic Prl receptors can be achieved
with hGH administered in osmotic minipumps. The
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FIGURE 8. Effect ofrPrl and rGH on hepatic Prl receptors in
hypophysectomized male rats. Oneweek afterhypophysectomy
(Hx), minipumps with rPrl orrGH, 10 ,ug/,ul, were implanted
in the animals of the groups indicated. One week later, Prl
receptors were measured. Numbers within brackets indicate
number ofanirnals in each group. Groups ofintact male and
female rats were also included. xx = p <0.01 when compared
to Hx male rats.
Prl-receptor-inducing activity of hGH was not de-
pendent on the presence of the pituitary, thyroid,
adrenals or gonads. The induction time was be-
tween 4 and 7 days.
Otherworkers have failed to see an effect ofhGH
on hepatic Prl receptor levels, although it was
administered three times aday in higher doses than
that used in the present investigation (79). This
may indicate that a continuous hormone adminis-
tration is necessary for induction. Since, to our
knowledge, it has not proved possible to study
hepatic Prlreceptor induction in an in vitro system,
osmotic minipumps would seem to be advantageous
to use in investigations on induction of Prl recep-
tors. The effect of hGH indicates that either a
lactogenic or a somatogenic or a combined principle
is responsible for Prl receptor induction. Any
definite conclusion as to the nature of the endoge-
nous hormone causing receptor induction cannot be
drawn. Due to the small quantities ofrPrl and rGH
available, we could only test these hormones at one
concentration. At this concentration, rPrl was not
effective in inducing hepatic Prl receptors. Also
previous experiments, where hypothalamic lesions
in male rats were found to lead to induction of
hepatic Prl receptors without a concomitant in-
crease in serum Prl (13, 81) support the contention
that Prlis not the main regulator ofPrlreceptors in
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athe liver. The same concentration of rGH as was
found to be without effect in case ofrPrlt resulted
in an increased hepatic Prl receptor level, although
not as high as in female rats. This would favor the
idea that the inducing hormone is GH or a GH-like
peptide. Further studies are required with more
purified preparations of rPrl and rGH as well as
with combinations of these hormones in order to
clarify this matter. Another possibility is that a
contaminant of the NIAMDD rGH B6 preparation
is the responsible hormone. In this context, it is
interesting to once more draw the attention to the
regulation ofthe sexdifferences in steroid and drug
metabolism in rat liver (43). Also here we have
proposed a novelpituitary factoracting onthe liver
(93). Considering the many similarities between
control ofsteroidmetabolism and Prlreceptors, the
same pituitary factor might be involved in both
cases.
General Comments
The hypothalamo-pituitary-liver axis represents
a new concept in endocrine regulation of drug
toxicity. The male rat liver has been shown to be
more susceptible than the female rat liver to the
hepatocarcinogenic action ofcertain drugs and it is
conceivable that sex differences in the metabolic
activation ofthe drugs in the liver may explain the
greater sensitivity of male rats to chemically in-
duced hepatocellular carcinoma. Similar sex differ-
ences in liver cancer incidence have been reported
inthehuman. Furtherstudiesonpituitary-regulated
metabolic activation of chemical carcinogens in the
liver may lead to a deeper understanding ofcontrol
of chemical carcinogenesis also in other tissues
regulated by pituitary hormones, e.g., the breast
and the prostate.
This study was supported by a grant from the Swedish
Medical Research Council (No. 13X-2819).
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